Sarah Chalk, APRN
Payments from drug & device makers
Across 161 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$606
- Lilly USA, LLC$215
- AbbVie$206
- GSK$192
- Otsuka America Pharmaceutical, Inc.$177
- Amgen$158
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,864100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $606 |
| Lilly USA, LLC | 12 | $215 |
| AbbVie | 10 | $206 |
| GSK | 12 | $192 |
| Otsuka America Pharmaceutical, Inc. | 10 | $177 |
| Amgen | 10 | $158 |
| Boehringer Ingelheim | 9 | $153 |
| Tris Pharma Inc | 8 | $135 |
| Exact Sciences | 6 | $110 |
| AstraZeneca | 4 | $78 |
| Inspire Medical Systems, Inc. | 2 | $76 |
| Bayer | 4 | $75 |
| Merck | 4 | $65 |
| Corium, LLC | 3 | $56 |
| Collegium Pharmaceutical, Inc. | 3 | $53 |
| Pfizer | 3 | $42 |
| Ironshore Pharmaceuticals Inc. | 2 | $41 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Cranial Technologies, Inc | 2 | $35 |
| Novartis | 2 | $35 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $34 |
| Acerus Pharmaceuticals Corporation | 2 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Alk-abello, Inc | 1 | $23 |
| Dexcom, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 2 | $22 |
| Viatris Specialty LLC | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Noven Therapeutics, LLC | 1 | $18 |
| Neos Therapeutics, LP | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
How this compares
$2,864 in reported general payments places this provider in the 85th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 14 | $288 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $247 |
| Gabapentin | 14 | $215 |
| Atorvastatin Calcium | 27 | $213 |
| Losartan Potassium | 12 | $180 |
| Levothyroxine Sodium | 21 | $179 |
| Fluoxetine Hcl | 18 | $164 |
| Escitalopram Oxalate | 14 | $155 |
| Methylprednisolone | 12 | $79 |
| Topiramate | 20 | $74 |
Paid to pharmacies, not to this prescriber.
Other family in Union
- Tanis BastUnion$38K
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.